Navigation Links
Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Date:8/6/2013

Study; and the use of pharmacotherapy to treat obesity. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the possibility that the FDA determines not to initiate review of the Contrave NDA until it has received the complete study report for the interim analysis; the SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; Orexigen's ability to conduct the Light Study and the progress and timing thereof, including risks associated with enrolling and retaining the appropriate patients in the Light Study; Orexigen's ability to demonstrate in the Light Study that the risk of MACE in overweight and obese patients treated with Contrave does not adversely affect Contrave's benefit-risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study; the potential for the FDA to not approve Contrave even after the resubmission with the MACE data; the potential for the Light Study to cost more than what is projected; the potential for early termination of Orexigen's North American collaboration agreement with Takeda Pharmaceutical Company Limited; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of the Contrave NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to maintain sufficient capital to fund our operations through potential approval of Contrave in 2014; the development plan for Empatic; Orexigen's ability to enter into a collaborative partnersh
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... LAS VEGAS , March 26, 2015 /PRNewswire/ ... worldwide sales agreement with Radlink, Inc., an emerging ... offer real-time image guidance with its hip replacement ... ongoing commitment to help improve patient outcomes, increase ... in conjunction with the 81st annual meeting of ...
(Date:3/26/2015)... 26, 2015  Oxis Biotech, Inc. (OXIS), ... Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] ... option agreement with the University of Pittsburgh ... Dr. Xiang-Qun Xie , Associate Dean ... School of Pharmacy.  These patents/intellectual properties relate ...
(Date:3/26/2015)... BUENA, N.J. , March 26, 2015 ... New Jersey based specialty generic pharmaceutical company, ... drug application (ANDA) to the U.S. Food and Drug ... number of ANDA submissions now pending at the FDA ... and CEO of the Company, commented, "On March 2, ...
Breaking Medicine Technology:DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 2DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 3Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 2Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 3IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2
(Date:3/26/2015)... “The SWEET Act is an important step ... available and help parents who are working to reduce sugar ... approach to support public health, and we will continue to ... health of all families,” said Dr. Jane Delgado President and ... introduction of the Sugar-Sweetened Beverage Tax (SWEET) Act by Congresswoman ...
(Date:3/26/2015)... 26, 2015 The Life Support ... to Hyperbaric Medicine” course, which is accredited by ... and the National Board of Diving & Hyperbaric ... course 4 times a year at several of ... tri-state region; registration is available on-line at: ...
(Date:3/26/2015)... The National League for Nursing, and ... has announced its partnership with Questionmark®, a supplier ... to accurately and securely measure knowledge, skills, and ... Questionmark’s state-of-the-art software and a custom-built portal, ... of the seventy-five to one hundred thousand exams ...
(Date:3/26/2015)... 26, 2015 In preparation for the ... Revolution, founded by Samir Becic, has issued “report ... personal health and fitness, as well as their promotion ... list includes Sen. Ted Cruz, who has officially announced ... all other politicians who have shown interest in running ...
(Date:3/26/2015)... 26, 2015 Zane Benefits, the leader ... a new eBook, “The Comprehensive Guide To Interviewing For ... is the most important aspect of the hiring process. ... hiring the right way, possibly resulting in thousands of ... arduous undertaking, yet it’s essential to the success of ...
Breaking Medicine News(10 mins):Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 3Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 4Health News:NLN Testing Services Announces Improved Delivery and Analytics Software and Newly Developed and Revised Exams 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3Health News:Zane Benefits Announces: New eBook: The Comprehensive Guide To Interviewing For Your Small Business 2
... Orthopedic,Group, Inc. (NYSE: HGR ) announces record revenue ... $0.18 per diluted share, for the quarter ended,September 30, ... increase in,net sales, a 24.6% increase in net income, ... pro-forma results for the third quarter of 2006. The,pro-forma ...
... the inaugural Mississippi Blues Marathon and,Half-Marathon, scheduled for January 5, 2008. Prize money will be awarded,in the following categories ... Male Female 1st Place $4,000 ... 3,000 3rd Place 2,000 2,000 4th ... 1,000 1,000, Wheelchair $500 ...
... Md., Oct. 29 The Cystic Fibrosis,Foundation was selected ... USA Track & Field (USATF), the national governing body ... The CF Foundation was honored for its largest fundraising ... nearly $32 million in 2006,and for other road races, ...
... are diagnosed with breast cancer at a younger age ... than Caucasian women, a Yale School of Medicine researcher ... Therapeutic Radiology and Oncology meeting in Los Angeles, ... Yale Cancer Center member, said her results were based ...
... important new research on the topics of cardiovascular ... kidney injury, racial and ethnic disparities of kidney ... being presented during the American Society of Nephrology,s ... Francisco at a policy-centered news briefing on Saturday, ...
... small, short-term trial is unlikely to quiet Natrecor,s critics , , ... the safety of Natrecor, a widely used heart failure medication, ... , Critics have charged that Natrecor, which costs about $500 ... may raise their risk of kidney failure and death. , ...
Cached Medicine News:Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 2Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 3Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 4Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 5Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 6Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 7Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 8Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 9Health News:Cystic Fibrosis Foundation Named Charitable Organization of the Year by USA Track & Field 2Health News:Breast cancer is more aggressive in African-American women 2Health News:Study Supports Controversial Heart Failure Drug 2Health News:Study Supports Controversial Heart Failure Drug 3Health News:Study Supports Controversial Heart Failure Drug 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: